Skip to main content
SpringerLink
Log in
Book cover
  • Book
  • © 2003

Novel Anticancer Drug Protocols

Editors:

  1. John K. Buolamwini

    1. University of Tennessee Health Science Center, Memphis

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Alex A. Adjei

    1. Mayo Clinic and Foundation, Rochester

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Methods in Molecular Medicine (MIMM, volume 85)

Sections

Buy it now

eBook USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

This is a preview of subscription content, log in via an institution to check for access.

Table of contents (26 protocols)

  1. Front Matter

    Pages i-xv
    PDF

  2. Introduction

    1. Front Matter

      Pages 1-1
      PDF

    2. Overview of Novel Anticancer Drug Targets

      • John K. Buolamwini, Haregewein Assefa
      Pages 3-28

  3. Kinase Inhibitor Discovery Protocols

    1. Front Matter

      Pages 29-29
      PDF

    2. Biomarker Assays for Phosphorylated MAP Kinase

      • Judith S. Sebolt-Leopold, Keri Van Becelaere, Kenneth Hook, Roman Herrera
      Pages 31-38

    3. Assays for Cyclin-Dependent Kinase Inhibitors

      • Adrian M. Senderowicz, Tyler Lahusen
      Pages 39-48

  4. Angiogenesis and Metastasis Protocols

    1. Front Matter

      Pages 57-57
      PDF

    2. The Rat Aortic Ring Assay for In Vitro Study of Angiogenesis

      • Ronald S. Go, Whyte G. Owen
      Pages 59-64

    3. Real Time In Vivo Quantitation of Tumor Angiogenesis

      • Gregory I. Frost, Per Borgström
      Pages 65-78

    5. Cell Motility, Adhesion, Homing, and Migration Assays in the Studies of Tyrosine Kinases

      • Martin Sattler, Elizabeth Quackenbush, Ravi Salgia
      Pages 87-105

    7. Binding Assay for Selectins

      • Jianing Zhang, Michiko N. Fukuda
      Pages 117-121

    8. Determination of Peak Serum Levels and Immune Response to the Humanized Anti-Ganglioside Antibody-Interleukin-2 Immunocytokine

      • Jacquelyn A. Hank, Jean E. Surfus, Jacek Gan, Amy Ostendorf, Stephen D. Gillies, Paul M. Sondel
      Pages 123-131

  5. Immunohistochemical Assays in the Clinical Setting

    1. Front Matter

      Pages 133-133
      PDF

    2. Immunohistochemical Determination of EGFR-Tyrosine Kinase Inhibition in Clinical Samples

      • Shazli N. Malik, Roble G. Bedolla, Manuel Hidalgo, Michael G. Brattain, Jeffrey I. Kreisberg
      Pages 135-140

  6. Protein Chaperoning/Degradation Protocols

    1. Front Matter

      Pages 147-147
      PDF

    2. Assays for HSP90 and Inhibitors

      • Wynne Aherne, Alison Maloney, Chris Prodromou, Martin G. Rowlands, Anthea Hardcastle, Katherine Boxall et al.
      Pages 149-161
Back to top

About this book

We are in an exciting era in the war against cancer, with real prospects for novel anticancer drugs that are cancer cell-specific without the toxicities that have been the hallmark of conventional cytotoxic cancer chemotherapy. Advances in cancer cell biology fueled by the molecular biology revolution have resulted in the uncovering of many novel potential molecular targets for cancer therapy. New anticancer drug discovery and development is now largely focused on exploiting these new molecular targets, which encompass oncogenes, tumor s- pressor genes, and their gene products, as well as targets involved in tumor angiogenesis, metastasis, survival, and longevity mechanisms. Exploitation of some of these targets has already yielded fruits and introduced new paradigms of molecularly targeted cancer therapy into the clinic, namely, protein kinase in- bition by antibodies or small molecules, exemplified by Herceptin® (trastuzumab), a humanized antibody targeted against the HER-2 growth factor receptor tyrosine kinase for the treatment of metastatic breast cancer; and Gleevec, a small molecule bcr-abl kinase inhibitor for the treatment of chronic myel- enous leukemia.
Back to top

Editors and Affiliations

  • University of Tennessee Health Science Center, Memphis

    John K. Buolamwini

  • Mayo Clinic and Foundation, Rochester

    Alex A. Adjei

Back to top

Bibliographic Information

  • Book Title: Novel Anticancer Drug Protocols

  • Editors: John K. Buolamwini, Alex A. Adjei

  • Series Title: Methods in Molecular Medicine

  • DOI: https://doi.org/10.1385/1592593801

  • Publisher: Humana Totowa, NJ

  • eBook Packages: Springer Protocols

  • Copyright Information: Springer Science+Business Media New York 2003

  • Hardcover ISBN: 978-0-89603-963-6Published: 26 March 2003

  • Softcover ISBN: 978-1-4899-3839-8Published: 16 August 2013

  • eBook ISBN: 978-1-59259-380-4Published: 01 February 2008

  • Series ISSN: 1543-1894

  • Series E-ISSN: 1940-6037

  • Edition Number: 1

  • Number of Pages: XVI, 355

  • Topics: Pharmacy

Back to top

Publish with us

Policies and ethics

Back to top
Access via your institution

Buy it now

eBook USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Search

Navigation